Landscapes / Targets
KRAS G12C
42 drugs act on KRAS G12C, in 49 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs42
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
KRAS G12C inhibitor |
Eli Lilly · Public LLY |
Phase 3 | Apr 2027Phase 1/2 trial completes | ||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms and 5 more | ||||
| Open drug page | |||||
PD-1 antibody |
Merck & Co. · Public MRK |
Phase 3 | Apr 2027Phase 1/2 trial completes | ||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms and 6 more | ||||
| Open drug page | |||||
— |
Phase 3 | 31 Dec 2027Phase 1/2 trial completes | |||
| Next date | 31 Dec 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Solid Tumor, NSCLC (Advanced Non-small Cell Lung Cancer) and 1 more | ||||
| Open drug page | |||||
KRAS G12C inhibitor |
Phase 3 | 31 Dec 2027Phase 3 trial completes | |||
| Next date | 31 Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer) | ||||
| Open drug page | |||||
KRAS G12C inhibitor |
Merck & Co. · Public MRK |
Phase 3 | 24 Jan 2028Phase 3 trial completes | ||
| Next date | 24 Jan 2028 · Phase 3 trial completes | ||||
| Also tested for | Non-small Cell Lung Cancer, Malignant Neoplasm | ||||
| Open drug page | |||||
— |
Hengrui · Public 600276.SS |
Phase 3 | May 2028Phase 3 trial completes | ||
| Next date | May 2028 · Phase 3 trial completes | ||||
| Open drug page | |||||
— |
Phase 3 | 31 Oct 2028Phase 2/3 trial completes | |||
| Next date | 31 Oct 2028 · Phase 2/3 trial completes | ||||
| Also tested for | Advanced Cancer, Metastatic Cancer and 11 more | ||||
| Open drug page | |||||
KRAS G12C inhibitor |
Roche · Public ROG.SW |
Phase 3 | 30 Nov 2028Phase 3 trial completes | ||
| Next date | 30 Nov 2028 · Phase 3 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Colorectal Cancer and 1 more | ||||
| Open drug page | |||||
— |
Phase 3 | Apr 2029Phase 3 trial completes | |||
| Next date | Apr 2029 · Phase 3 trial completes | ||||
| Also tested for | NSCLC | ||||
| Open drug page | |||||
PD-L1 antibody |
AstraZeneca · Public AZN |
Phase 3 | May 2029Phase 3 trial completes | ||
| Next date | May 2029 · Phase 3 trial completes | ||||
| Also tested for | Carcinoma, Non-Small-Cell Lung | ||||
| Open drug page | |||||
— |
Phase 3 | 31 May 2030Phase 3 trial completes | |||
| Next date | 31 May 2030 · Phase 3 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Advanced Solid Tumors and 1 more | ||||
| Open drug page | |||||
— |
Phase 3 | — | |||
| Also tested for | Non Small Cell Lung Cancer | ||||
| Open drug page | |||||
— |
Phase 2 | 31 Dec 2026Phase 2 trial completes | |||
| Next date | 31 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | KRAS P.G12C, Advanced Colorectal Cancer and 7 more | ||||
| Open drug page | |||||
— |
Novartis · Public NVS |
Phase 2 | 25 Jan 2027Phase 1/2 trial completes | ||
| Next date | 25 Jan 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal and 7 more | ||||
| Open drug page | |||||
— |
Novartis · Public NVS |
Phase 1/2 | 25 Jan 2027Phase 1/2 trial completes | ||
| Next date | 25 Jan 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal and 7 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Mar 2027Phase 1/2 trial completes | |||
| Next date | Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | KRAS P.G12C, Non-small Cell Lung Cancer and 2 more | ||||
| Open drug page | |||||
PD-1/VEGF bispecific antibody |
Akeso +1 · Public 9926.HK · SMMT |
Phase 2 | 30 Apr 2027Phase 2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 30 Apr 2027 · Phase 2 trial completes | ||||
| Open drug page | |||||
— |
Phase 1/2 | Apr 2027Phase 1/2 trial completes | |||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | KRAS P.G12C | ||||
| Open drug page | |||||
RAS inhibitor (active RAS, several mutations) |
Phase 1/2 | Jun 2027Phase 1/2 trial completes | |||
| Next date | Jun 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer and 5 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Jun 2027Phase 1/2 trial completes | |||
| Next date | Jun 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer and 5 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 42 of 42 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026